11/25/2023 0 Comments Keynote 590 trialIn China, EC is the fourth most common cause of mortality, with 30.1 deaths per 100,000 in 2020 ( 2, 3). The crude mortality rate of EC was 7.8/100,000 in 2020, which represented 5.5% of all cancer deaths and ranked as the sixth most common cause of cancer death ( 1). The sensitivity analysis demonstrated that the ICERs were most sensitive to the cycle of pembrolizumab used and the cost of pembrolizumab.Ĭonclusion: The result of our present analysis suggests that the addition of pembrolizumab plus chemotherapy as first-line treatment might not be cost-effective for patients with ESCC and PD-L1 CPS of 10 or more in China.Įsophageal cancer (EC) is one of the most common malignant tumors in the world. chemotherapy alone added 1.23 QALYs and resulted in an incremental cost of $51,320.22, which had an ICER of $41,805.12/QALY, higher than the willingness-to-pay (WTP) threshold of China ($37,663.26/QALY). Results: The baseline analysis indicated that the incremental effectiveness and cost of pembrolizumab plus chemotherapy vs. One-way and probabilistic sensitivity analyses were conducted to check the stability of the model. Utility values and direct costs related to the treatments were gathered from the published literature data. chemotherapy alone in first-line treatment of ESCC and PD-L1 CPS of 10 or more. Methods: Based on the advanced ESCC of the KEYNOTE-590 clinical trial data, a Markov model was performed to simulate the clinical course and evaluate the patient's total lifetime, total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) for pembrolizumab plus chemotherapy (cisplatin and 5-fluorouracil) vs. 2Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Chinaīackground: This study aimed to analyze the economics of pembrolizumab plus chemotherapy as first-line treatment in patients with esophageal squamous cell carcinoma (ESCC) and programmed cell death-Ligand 1 (PD-L1) combined positive score (CPS) of 10 or more in China.1Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China. Zhiwei Zheng 1 † Jingrong Lin 1 † Huide Zhu 1 * Hongfu Cai 2 *
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |